Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck's German-listed shares closed down 3. ... has been approved in the United States. The company is expecting the approval of a product that treats neurofibromatosis type-1, a rare genetic ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

We recently compiled a list of the 10 Best Dow Jones Dividend Stocks According to Wall Street Analysts. In this article, we ...

Merck, in a statement ... has been approved in the United States. The company is expecting the approval of a product that treats neurofibromatosis type-1, a rare genetic disorder, later in ...

NEW YORK/FRANKFURT — Merck KGaA, the German health care and technology group, said on Monday it is in advanced talks to acquire US cancer and rare diseases drugmaker SpringWorks Therapeutics. Merck, ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...